Oncology

dollar sign with colored arrows in a maze
Biotech

Pfizer Ventures gets behind Chinese biotech's $100M series A

Pfizer’s VC arm has backed a $100 million raise for OTR as the Chinese biotech tacks on preclinical neurological assets to its varied portfolio.
James Waldron Dec 5, 2025 4:20am
layoffs cut staff reduction workforce

Genetic medicines biotech halves team

Nov 20, 2025 10:15am
Assortment of tools laid out on wooden background

Repare nails down XenoTherapeutics buyout

Nov 17, 2025 12:12pm
Clear out clearnance rubbish scrap heap

Bayer bails on Vividion tumor drug in early-stage clear-out

Nov 12, 2025 8:10am
pipeline pipes RD research

Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus

Nov 6, 2025 1:26pm
Novo Nordisk

Novo drops oncology ambitions, early-stage MASH prospects

Nov 5, 2025 7:21am
More News

GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets

Oct 29, 2025 6:29am

Cardiometabolic field drives M&A while cancer deals drop: report

Oct 27, 2025 2:39pm

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am

Boehringer digs in on ADCs with $991M AimedBio licensing accord

Oct 15, 2025 10:05am